Management of venous thromboemlism disease in psychiatric patients

##plugins.themes.academic_pro.article.sidebar##

Published Jan 25, 2012
Download
pdf
Vol. 90 No. 1 (2012): Issue Jan 2012

##plugins.themes.academic_pro.article.main##

Naziha Khammassi
Abdelhedi Haykel
Ouahida Cherif

Abstract

Background: Several studies conducted in psychiatric populations, have reported the promoting and pejorative role of psychiatric community in thrombogenesis.
Aims: To clarify the specificity of psychiatric community in deep vein thrombosis (DVT) and to propose a set of general recommendations for appropriate care.
Methods: We searched MEDLINE (PubMed) between 1956 and 2010. We reviewed article titles and abstracts and full text of selected studies of psychiatric patients with venous thromboembolism disease. We identified 50 studies that investigated the association between psychiatric disease and venous thromboembolism events.
Results: In psychiatric community venous thromboembolism disease has several characteristics: epidemiological, clinical and evolutionary and is conditioned by a combination of several thromboembolism risk factors:
- Linked in part to the psychiatric illness itself,
- But above all specific therapeutic methods in psychiatric community (anti-psychotic, restraint...) which are easily preventable.
Conclusion: Besides the medical side, the psychiatric community itself is characterized by a large number of variables, giving a particularly encouraging and derogatory about the advent and development of VTE.

Keywords:

Venous thrombosis; psychiatric disorder; antipsychotics

##plugins.themes.academic_pro.article.details##

References

  1. Le Jeune S, Pistorius MA, Planchon B et al. Risque thromboembolique veineux au cours des affections médicales aiguës. Partie 2 : situations à risque en milieu ambulatoire, en milieu médical hospitalier et en médecine interne. Rev Med Interne 2008; 29 : 462-75.
  2. Le Jeune S, Pistorius MA, Planchon B et al. Risque thromboembolique veineux au cours des affections médicales aiguës. Partie 1 : modèles pathogéniques fondamentaux et cliniques, épidémiologie descriptive et analytique. Rev Med Interne 2008 ; 29 : 452-61.
  3. Knudson JF, Kortepeter C, Dubitsky GM, et al. Antipsychotic drugs and venous thromboembolism. Lancet 2000 ; 356 : 252-3.
  4. Vandenbroucke JP, Bertina RM, Holmes ZR, et al. Factor V Leiden and fatal pulmonary embolism. Thromb Haemostasis 1998 ; 79 : 511-16.
  5. Mielke FA, Uber das Rauwolfia. Alkaloid Reserpin (Serpasil) in der Psychiatric. Arch Psychiatry 1956 ; 194 : 263.
  6. Grahmann H, Suchewirth R. Die Thrombosegefahr bei der Chlorpromazin und Reserpine behandlung endogener Psycosen. Nervenarze 1959; 30: 224.
  7. Hafner H, Brehm I. Thromboembolic complications in neuroleptics treatment. Comprehensive Psychiatry 1965; 6: 25-34
  8. Varia I, Krishnan RR, Davidson J. Deep vein thrombosis with antipsychotic drugs. Psychiatry 1983; 24: 1097-98.
  9. Regland B, Johansson BV, Grenfeldt B et al. Homocysteinemia is a common feature of schizophrenia. J Neural Transm 1995; 100: 165-9.
  10. Susser E, Brown AS, Klonowski E et al. Schizophrenia and impaired homocysteine metabolism : a possible association. Biological Psychiatry 1998 ; 44 : 141-3.
  11. Levine J, Stahl Z, Sela BA et al. Elevated homocysteine levels in young male patients with schizophrenia. Am J Psychiatry 2002; 159: 1790-2.
  12. Godfrey PS, Toone BK, Carney MW et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet 1990 ; 336 : 392-5.
  13. Ueland PM, Refsum H, Brattstrom L. In: Francis RB, eds. Plasma homocysteine and cardiovascular disease. Atherosclerotic cardiovascular disease, hemostasis and endothelial function. New York : Marcel Dekker, 1993 : 183-236.
  14. Rees MM, Rodgers GM. Homocysteinemia: association of a metyabolic disorder with vascular disease and thrombosis. Thromb Res 1993; 71: 337-59.
  15. Rodgers GM, Kane WH, Pitas RE. Formation of factor Va by atherosclerotic rabbit aorta mediates factor Xa-catalyzed prothrombin activation. J Clin Invest 1988 ; 81 : 1911-9.
  16. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood 1990 ; 75 : 895-901.
  17. Matti J, Markku H, Paul K et al. Mental disorders and cause specific mortality. Br J Psychiatry 2001; 179: 498-502.
  18. Awad AG. Quality of life measurements in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol Med 1988; 28: 165-72.
  19. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997; 171: 502-6.
  20. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11-53.
  21. Zornberg GL, Hershel J. Antipsychotic drug use and risk of firsttime idiopathic venous thromboembolism: a case -control study. Lancet 2000; 356: 1219-23.
  22. Aslv K, Aygun E, Elif Anvl Y et al. Venous thromboembolism and escitalopram. Gen Hosp Psychiatry 2004; 26: 481-83.
  23. Lederbogen F, Gilles M, Maras A et al. Increased platelet aggregability in major depression? Psychiatry Res 2001; 102: 255-261.
  24. Glassman A, Shapiro PA. Depression and the course of coronary artery disease. Am J Psychiatry 1998; 155 : 4-11.
  25. Musselman DL, Evans DL, Nemeroff CB. The relation ship of depression to cardiovascular disease : Epidemiology, biology and treatment. Arch Gen Psychiatry 1998 ; 55 : 580-92.
  26. Newman SC, Bland RC. Suicide risk varies by subtype of affective Disorder. Acta Psychiat Scand 1991 ; 83 : 420-6
  27. Sharma R, Markar HR. Mortality in affective disorder. J Affect Disord 1994 ; 31 :91-6.
  28. Gianluca T, Spinaa E, Gambassic G. Use of antipsychitics in elderly patients with dementia : Do atypical and conventional agents have a similar safety profile? Pharmacol Res 2009; 59: 1- 12.
  29. Hagg S, Tatting P, Spigset O. Olanzapine and venous thromboembolism. Int Clin Psychopharmacol 2003 ; 18 :299-300.
  30. Waage IM, Gedde-Dahl A. Pulmonry embolism possibly associeted with Olanzapine treatment. BMJ 2003 ; 327 : 1384.
  31. HAMANAKA S, Kamijo Y, Nagai T et al. Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circ J 2004 ; 68 :850-2.
  32. Liperoti R, Pedone C, Lapane KL et al. Venous thromboembolism among elderly patients treated with atypical and conventional antipsychotic agents. Arch Intern Med 2005 ; 165 : 2677-82.
  33. Hagg S, Bate A, Stahl M, et al. Association between venous thromboembolism and antipsychotics : a study of the WHO database of adverse drug reaction. Drug Saf 2008 ; 31 : 685-94.
  34. Thorogood M, Cowen P, Mann J et al. Fatal myocardial infarction and use of psychtropic drugs in young. Lancet 1992 ; 340 : 1067- 8.
  35. Yoshito K, Kazui S, Tomonori N et al. Acute massive pulmonary thromboembolism associated with Risperidone and conventional phenothizines. Circ J 2003 ; 67 : 46-48.
  36. Bordet R. Neuroleptiques ou antipsychotiques ? typiques ou atypiques ? La lettre du pharmacologue 2004 ; 18 : 81-6.
  37. Boullin DJ, Orr MW. Effects of aspirin and prostaglandin E2 on secondary phase aggregation responses of schizophrenic patients treated with chlorpromazine. Br J clin. Pharmac 1976 ; 3 : 929-33.
  38. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia : mechanism, clinical features and management. Drugs 2004 ; 64 : 2291-314.
  39. Goodnick PJ, Rodriguez L, Santana O. Antipsychotics : Impact on prolactin levels. Expert Opin Pharmacother 2002 ; 3 : 1381-91.
  40. Ramot Y, Nyska A. Drug-induced Thrombosis : Experimental, clinical, and mechanistic considerations. Toxicologic Pathology 2007 ; 35 : 208-25.
  41. Lewin PK. The use and abuse of restraints. CMAJ 1998; 159: 1239-41.
  42. Laursen SB, Jensen TN, Bolwig T et al. Deep venous thrombosisand pulmonary embolism following physical restraint. Acta Psychiat Scand 2005; 111: 324-7.
  43. Hem E, Steen O, Opjordsmoen S. Thrombosis associated with physical restraints. Acta Psychiat Scand 2001 ; 103 : 73-5.
  44. Singh G, Wahi S. Pulmonary embolism in the ECT patient: a case report and discussion. Gen Hosp Psychiatry 2008; 30: 87-9.
  45. George AM, Robert ES, Richard BD. Intracardiac thrombi in patients undergoing electroconvulsive therapy. Am Heart J 1990; 119: 684-685.
  46. Lacut K, Mottier D, Pottier P. Médicaments et maladie veineuse thromboembolique. Rev Pneumol Clin 2008 ; 64 : 290-7.
  47. Oomen HA, Wekking FM, De Jong J et al. Screening psychiatric admissions for anticardiolipin antibody. Psychiatry Res 1995; 58: 83-8.
  48. Chengappa KN, Carpenter AB, Keshavan MS et al. Elevated IGG and IGM anticardiolipin antibodies in a subgroup of medicated and unmedicated schizophrenic patients. Biol Psychiatry 1991; 30: 731-5.
  49. Schwarts MD, Rochas M, Weller B et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry 1998; 59: 20-3.
  50. Canoso RT, De Oliveira RM. Chlorpromazine-induced anticardiolipin antibodies and lupus anticoagulant: absence of thrombosis. Am J Hematol 1988; 27: 272-5.